UNSPSC 51432301: Ciprokiren

This classification denotes an antihypertensive agent with the molecular formula C37H55N5O8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, K259Z4O1B3 chemically known as (.alpha.s)-n-((1s,2r,3s)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-.alpha.-((.alpha.s)-.alpha.-(((1-methyl-1-(morpholinocarbonyl)ethyl)sulfonyl)methyl)hydrocinnamamido)imidazole-4-propionamide but generally known as ciprokiren, which bears US NIH Compound Identifier 64925.

UNSPSC 51432301 Ciprokiren is a Commodity code covering specific pharmaceutical active ingredients and related drug products procured by state and local health authorities. State and local governments buy ciprokiren and similar active pharmaceutical ingredients primarily through two channels: direct procurement for emergency medical services and fire-rescue operations, and cooperative purchasing agreements administered by multistate alliances serving broader government healthcare networks. The City of Tampa's sealed-bid procurement for Advanced Life Support Medications (Bid No. 26-P-00188) exemplifies the first channel—direct acquisition of specific drug formulations for use by Tampa Fire Rescue, including epinephrine, labetalol, adenosine, and diltiazem vials required to maintain nine-month minimum shelf life with firm pricing including freight and taxes. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for Generic Multi Source Pharmaceuticals and OTC Products represents the second—a formal manufacturer contracting vehicle through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) to supply multiple state and local government facilities across participating jurisdictions including Oregon, with evaluation weighted heavily on price competitiveness (75 percent) and compliance with cGMP and Drug Supply Chain Security Act (DSCSA) standards. Issuing bodies include municipal fire departments and purchasing offices (Tampa), state health commissions (Texas Health and Human Services Commission), and regional cooperative purchasing alliances (MMCAP, administered by the Minnesota Department of Administration). Tampa's bid includes a Small Local Business Enterprise (SLBE) sheltered market designation with a 5 percent bid discount, not to exceed $10,000.

Recent activity concentrates in Florida and Minnesota, with strategic-procurement activity also present in Texas. The Tampa IFB closed April 8, 2026, with an estimated contract value of $40,000 and one-year term plus optional renewals and 30-day extensions at the city's discretion. The MMCAP RFP, posted January 20, 2026, with a response deadline of March 26, 2026, establishes two-year manufacturer contracts effective July 1, 2026, through authorized wholesalers, requiring vendors to maintain commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. The Texas Health and Human Services Commission's Request for Information (RFI No. HHS0017013), posted April 3, 2026, sought exploratory vendor capabilities regarding direct-to-manufacturer prescription fulfillment models for the state's Therapeutic Pharmacy Initiative, with response due April 3, 2026, designed to inform future formal procurement strategy rather than award immediate contracts.